Ga-68 PSMA-11 PET/CT Scan for Cancer

Recruiting in Palo Alto (17 mi)

Overseen byBrian J. Burkett, M.D., M.P.H.

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Mayo Clinic

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This phase II trial tests whether gallium-68 (Ga-68) prostate specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) imaging is useful for detecting therapy response in patients with adenoid cystic carcinoma (salivary gland cancer) that has spread from where it first started (primary site) to other places in the body (metastatic). The PET scan detects and takes pictures of where the radioactive imaging agent (68Ga PSMA-11) has gone in the body and the CT scan uses x-rays to create images of the bones and internal organs within the body. Combining a PET scan with a CT scan can help make the images easier to interpret. This study may help researchers learn whether GA-68 PSMA-11 PET/CT is useful for detecting treatment response and guiding treatment decisions in patients with metastatic adenoid cystic carcinoma.

Eligibility Criteria

This trial is for patients with adenoid cystic carcinoma, a type of salivary gland cancer that has spread to other body parts. The eligibility criteria are not fully listed but typically include factors like the stage of cancer, prior treatments received, and overall health status.

Inclusion Criteria

Willingness to return for a second PSMA PET/CT scan in approximately 12-20 weeks from the baseline PET/CT

I have been diagnosed with metastatic adenoid cystic carcinoma.

Enrolled in protocol MC200708

+3 more

Exclusion Criteria

Unable to undergo PET/CT scan

Not a participant in MC200708

I am under 18 years old.

+2 more

Participant Groups

The trial is testing if a new scan using Ga-68 PSMA-11 PET/CT can effectively detect how well treatment is working in patients with metastatic adenoid cystic carcinoma. It combines radioactive imaging and x-ray technology to create detailed images of the body's response to therapy.

1Treatment groups

Experimental Treatment

Group I: Diagnostic (Ga-68 PSMA-11, PET/CT)Experimental Treatment4 Interventions

Patients receive Ga-68 PSMA-11 IV and then undergo PET/CT 50-70 minutes after injection at baseline and approximately 12-20 weeks during investigational therapy.